Capricor Therapeutics (CAPR) logo

Capricor Therapeutics (CAPR) stock

Pre-market
$9.42
-1.15%

Cell-based therapies, worth $595MSmall-cap biotech

Close $9.53 -6.93%

Quality Score
-7
Poor
In its industry
#230of 270
Checks firing
2of 14
Trending down
From 52-week high
-76.4%
under its best in a year

CAPR's Quality Score fell 1 point on Fri, Nov 13, to -7. Its daily price swings got bigger.

Follow CAPR's trial news. Pro members can get an alert when Capricor Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CAPR files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextNov 22, 2026 · In 6 days“…(BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026”FDA decision date · SEC filing · Nov 10
Cash$198M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into Q4 2027”

Key facts on CAPR

Key facts on CAPR
Holding it back27.2% more shares than a year ago from Massive's market data
Latest filing8-K, Nov 10 Reported its quarterly results
1 more reason behind CAPR's -7, free with an account →4 more reasons behind CAPR's -7, for Pro members.

CAPR in the news

Wed Nov 11Capricor Therapeutics reported a loss of $0.73 a share SEC, 4:05 PM ET CAPR closed +26.5% that day.

Cash$198M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into Q4 2027”

CAPR catalysts

Coming up

After its last 4 reports it closed +18.0% on average, higher 2 of 4 times.

4 past catalysts since 2024, with sizes and sources, for Pro members.

What's next for CAPR, and how long its cash lasts

Next step the company has named

Nov 22In 6 days“Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026”FDA decision date · SEC filing · Nov 10

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

More on Deramiocel's FDA date

Lead program
Deramiocel · under FDA review

2 more trials, 38 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 6 quarters

$198M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into Q4 2027” (8-K, May 12).

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Sep 10, 2025)
  • At-the-market share sales program (S-3, filed Sep 10, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO Anthony Bergmann sold 24,100 shares on Jun 25. 9 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Linda Marban’s 3 filings and quotes.

Get an alert before CAPR's FDA date

A free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

Why CAPR scores -7

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

-7 is below -5, off the left end of the scale.

  • +2Chart checks 2 of 14 firing right now, one point each
  • −2Long-term trend below a falling 200-⁠day average, down over two years
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Persistence, and News.

What every line is worth, and the reason behind it, on CAPR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:03 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when CAPR's Quality Score turns up

A free account. No card.Pro, 7 days free with a card.

How CAPR ranks in Biotech

CAPR is #230 of 270 by Quality Score.

How CAPR ranks in Biotech
RankStockQuality Score
230Capricor Therapeutics (CAPR) logoCAPRCapricor Therapeutics-7

Cash and short-term investments: CAPR $198M, AGIO $630M, SVRA $130M, INO $48.4M.

More in Biotech

When does CAPR report earnings, and what happens after?

Expected to report Thu Mar 11, after the close (in 115 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CAPR reported on Nov 10, 2026

The quarter

A loss of $0.73 a share, from $0.54.

“The increase was primarily driven by pre-commercial activities and manufacturing scale-up.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

CAPR's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The Company expects to provide additional guidance on its longer-term financial outlook following greater regulatory clarity, which will inform future strategic and capital allocation decisions.”

From its results filing (SEC filing · Nov 10)

The numbers

Market value
$595M
today
Sales
$0
down 100% on the year
Loss
$105M
last fiscal year
Free cash flow
-$72.7M
last fiscal year

Its share count grew 15% a year over 5 years.

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CAPR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-3.8%+58.0%+26.5%
May 12Aug 13Nov 10
ReportedGapReaction5
days
Nov 10, 2026After close+8.8%+26.5%not yet
Aug 13, 2026After close+82.0%+58.0%+62.4%
May 12, 2026After close-2.7%-3.8%-14.6%

CAPR closed higher after 2 of its last 4 reports.

All 4 reports, and CAPR's Quality Score going into each

CAPR sales and profit by year

Sales and profit by year

Sales grew in two of the last seven years, to $0 in 2025. It lost money in each of the eight years.

CAPR has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on CAPR, and all 14 on every stock.Get in free →

CAPR RSI on Nov 13: 57.2, above its 50-day, below its 200-day

Not scored

RSI 57.2, MACD above signal, above its 50-day, below its 200-day. Not scored.

The deep dive on CAPR

9 more findings on CAPR, each with its source, for Pro members.

CAPR share count over time

27% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of CAPR outstanding, as filed
Shares
outstanding
As
of
58.1MNov 9, 2026
58.1MAug 13, 2026
57.9MMay 11, 2026
57.5MMar 16, 2026
Offerings, shelves, and splits of CAPR, from its filings
From its
filings
Filed
Raised $150M in a sale of shares, about 25% of its market valueDec 5, 2025
Registered shares for a later sale (S-3)Sep 10, 2025
Registered shares for a later sale (S-3)Oct 22, 2024
Raised $75M in a sale of shares, about 13% of its market valueOct 17, 2024

CAPR insider trades

2 insiders sold $1.5M across 6 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellKaren Krasney$732KEVP, General Counselat $30.38 on Jun 25, filed Jun 29

All 6 insider filings on CAPR from the last six months, for Pro members.

All CAPR insider trades

CAPR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold CAPR?

In ETFs: CAPR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

231 employeesSan Diego, CAcapricor.com

What Capricor Therapeutics says it competes with

“We are engaged in fields that are characterized by extensive worldwide research and competition.”

From its annual report, SEC filing · Mar 17, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on CAPR and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn CAPR's score around: 9 things
  • 7 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayJun 29Karen Krasney sold CAPR$732K at $30.38, filed Jun 29

Alerts are optional.

See CAPR's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: CAPR's Quality Score is -7 (Poor), #230 of 270 in Biotech. Insiders sold $1.5M in the last 6 months (Form 4).

What does CAPR's Quality Score say?

CAPR scores -7 today, which Breakaway calls Poor. It is #230 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CAPR's Quality Score?

CAPR scores -7 today, which Breakaway calls Poor (below zero). That is #230 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CAPR's -7.

Are insiders buying CAPR?

2 insiders sold $1.5M across 6 filings in the last 6 months. No open-⁠market buys on record. The newest is Karen Krasney, EVP, General Counsel, who sold $732K on Jun 25. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Capricor Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.